We helped our client commercialize a new antiviral therapy to treat acute COVID-19 among people who continue to be high-risk for serious illness despite vaccinations and other prevention measures.

We helped our client forge new connections with patient organizations worldwide while amplifying efforts to address and advocate for vital aspects of anti-infective treatments.

We helped our client transition to a new vaccine formulation for meningitis across seven countries.